IUPUI Research Day

Permanent URI for this community

https://hdl.handle.net/1805/4255
Research Day provides an opportunity for the IUPUI faculty, staff, and students, and their academic, industrial, governmental partners, and the broader community, to come together and learn more about the research enterprise at IUPUI, explore new collaborations, and lay the foundation for new partnerships. IUPUI Research Day is sponsored by the IUPUI Office of the Vice Chancellor for Research.

Browse

Browsing IUPUI Research Day by Author "Abeysekera, Irushi S."

Now showing 1 - 5 of 5
  • Thumbnail Image
    Item
    Effects of Epigallocatechin-3-gallate Treatment on Cognitive Deficits in a Down Syndrome Mouse Model
    (Office of the Vice Chancellor for Research, 2014-04-11) Dhillon, Hardeep; Abeysekera, Irushi S.; Stringer, Megan
    Down syndrome (DS) is caused by three copies of human chromosome 21 (Hsa21) and results in a constellation of phenotypes that include intellectual disability (ID) and skeletal abnormalities. Ts65Dn mice, the most extensively studied model of DS, have three copies of approximately half the genes on Hsa21 and display many DS related phenotypes including skeletal and ID deficits. DYRK1A is found in three copies both in humans with DS and in Ts65Dn mice; DYRK1A has increased expression in humans with DS and is involved in a number of critical pathways including CNS development and osteoclastogenesis. Epigallcatechin-3-gallate (EGCG), the main polyphenolic compound found in green tea, inhibits Dyrk1a activity, and we have shown previously that a three-week treatment with EGCG during adolescence normalizes some skeletal abnormalities in Ts65Dn mice. The current study tested the hypothesis that a similar 3-week treatment with EGCG will also rescue cognitive deficits observed in Ts65Dn mice. Trisomic mice and euploid littermates were given EGCG or water (control) for three weeks during adolescence. Following termination of the treatment, the mice were tested sequentially (over 5 weeks) on locomotor activity (two daily 30-min sessions in an activity chamber), novel object recognition (NOR) memory, acquisition of delayed non-matching to place (DNMP) spatial working memory in a tmaze, or spatial learning and memory in the Morris water maze (MWM). Results to date indicate that Ts65Dn mice exhibit deficits in the learning and memory tasks compared to controls, but the 3-week EGCG treatment did not significantly improve their performance.We hypothesize that for EGCG to be effective for improving cognitive deficits of the Ts65Dn mice, it needs to be present in the brain during the behavioral testing period; our ongoing studies are testing this with continuous EGCG treatment throughout the behavioral testing process.
  • Thumbnail Image
    Item
    EGCG from different sources: differential stability and effects on treating bone phenotypes related to Down syndrome
    (Office of the Vice Chancellor for Research, 2014-04-11) Thomas, Jared R.; Abeysekera, Irushi S.; Blazek, Joshua D.; Roper, Randall J.
    Down Syndrome (DS) is a genetic disorder caused by trisomy of human chromosome 21 (Hsa21). DS phenotypes include cognitive impairment, craniofacial abnormalities, low muscle tone, and skeletal deficiencies. The Ts65Dn mouse model exhibits similar phenotypes as found in humans with DS, including deficits in skeletal bone. Over-expression of DYRK1A, a serine-threonine kinase encoded on Hsa21, has been linked to deficiencies in DS bone homeostasis. Epigallocatechin-3-gallate (EGCG), an aromatic polyphenol found in green tea (GT), is a known inhibitor of Dyrk1a activity. Normalization of Dyrk1a activity by EGCG may have the potential to regulate bone homeostasis, by increasing bone mineral density (BMD) and bone strength. We hypothesized that EGCG obtained from different vendors would differ in stability as well as success in ameliorating skeletal deficiencies. EGCG from different sources was subjected to degradation analysis because of its low bioavailability due to strong antioxidative characteristics. We also hypothesized that phosphoric acid would stabilize EGCG and prevent breakdown in an aqueous solution. We performed High Performance Liquid Chromatography–Mass Spectrometry (HPLC-MS) on EGCG from different sources to determine the amount of EGCG degradation in solution. Our analyses showed differential stability in EGCG from different sources or with phosphoric acid. We chose EGCG from three sources to test the hypothesis that these compounds would have differing effects treating bone phenotypes associated with DS. Three-week-old Ts65Dn and control male mice were treated with EGCG for three weeks. At six weeks of age, mice were sacrificed and femurs were extracted. BMD, bone strength, as well as architecture of the femur were assessed. Our results indicate that EGCG from different sources has diverse effects on the correction of bone phenotypes associated with DS. Our work is important to understand how EGCG from different sources may affect DS phenotypes as the EGCG is translated to human use.
  • Thumbnail Image
    Item
    EGCG Treatment on Ts65Dn Mice Suggests a Possible Correlation in Cognitive Development Deficit Reduction
    (Office of the Vice Chancellor for Research, 2014-04-11) Taboada, Maria Fatima Delgado; Abeysekera, Irushi S.; Roper, Randall J.
    Down syndrome (DS) is caused by trisomy of human chromosome 21 (Ts21), affecting 1 in 700 live births. Ts21 results in about 80 phenotypes of which intellectual disability (ID) is one of the most debilitating. DYRK1A, found in 3 copies in individuals with Ts21 has been linked to alterations in morphology and function of the brain resulting in ID. Epigallocatechin-3-gallate (EGCG), a specific inhibitor of Dyrk1a activity has been hypothesized as a possible treatment for the overexpression of this gene, reducing the deficits caused by Dryk1a. Using the Ts65Dn mouse model, we examined the effects on hippocampal dependent learning and memory in the novel object recognition task (NOR) using mice of 3-6 weeks of age (adolescent mice). They were given free access to EGCG (0.124 mg/mL) in their drinking water for 21 days. They were then tested for cognitive improvement through NOR. Ts65Dn and control mice (treated and untreated) were subjected to 3 days of testing with 15 minute sessions per day consisting of habituation, exposure, and test day. All procedures were recorded and analyzed to determine time spent exploring novel object in relation to familiar. Our current results suggest that s65Dn mice do not spend as much time exploring the novel object as euploid mice and there exists a genotype effect, but treatment is not correcting the learning and memory deficit. We hypothesize that continuous EGCG treatment may be needed in order to see cognitive deficit reduction in adolescent mice.
  • Thumbnail Image
    Item
    Evaluation of osteoclastogenesis in the Ts65Dn Down Syndrome Mouse Model
    (Office of the Vice Chancellor for Research, 2015-04-17) Abeysekera, Irushi S.; Raje, Kimaya; Roper, Randall J.
    Down Syndrome (DS) affects ~1 in 700 live births and is caused by trisomy of human chromosome 21 (Hsa21). DS is characterized by a wide spectrum of phenotypes including cognitive and skeletal abnormalities that affect all individuals with DS. To study these phenotypes, we utilize the Ts65Dn mouse model, which contains three copies of approximately half the gene orthologous found on Hsa21 and exhibits similar phenotypes as found in humans with DS. Individuals with DS and Ts65Dn mice have deficits in bone mineral density (BMD), bone architecture, and bone strength. Three copies of DYRK1A, a serine-threonine kinase encoded on Hsa21, has been linked to deficiencies in bone homeostasis in DS mouse models and individuals with DS. DYRK1A is thought to act via NFATc1, a master regulator of osteoclastogenesis. Epigallocatechin-3-gallate (EGCG), a polyphenol found in high concentrations in green tea, is a known inhibitor of DYRK1A activity. We propose that the DS bone phenotype arises from an increase in osteoclastogenesis and/or maturation which results in increased bone resorption and disrupted bone homeostasis. We hypothesize that treatment of the mice during adolescence with 100 mg/kg/day EGCG would result in normalization of osteoclast numbers in trisomic mice to that of the controls. Osteoclast precursors from femur and spleen were isolated from 8-10 week old mice treated with 100 mg/kg/day EGCG or water from three weeks of age onwards. The cells were grown in the presence of M-CSF & RANK-L to promote osteoclast differentiation. Following 3 weeks in culture, the cells were fixed, TRAP stained, and multinucleated osteoclasts from control and Ts65Dn treated and untreated mice were counted. Mentor: Randall Roper, Department of Biology, IUPUI School of Science, Indianapolis, IN
  • Thumbnail Image
    Item
    Evaluation of the Effects of Green Tea Extracts on Bone Homeostasis in the Ts65Dn Down Syndrome Mouse Model
    (Office of the Vice Chancellor for Research, 2013-04-05) Abeysekera, Irushi S.; Thomas, Jared R.; Blazek, Joshua D.; Roper, Randall J.
    Down Syndrome (DS) is a genetic disorder that affects ~1 in 700 live births, caused by trisomy of human chromosome 21 (Hsa21), and results in cognitive impairment, craniofacial abnormalities, low muscle tone, and skeletal deficiencies. To study these phenotypes, we utilized the Ts65Dn mouse model, which contains three copies of approximately half the orthologous found on Hsa21 and exhibits similar phenotypes as found in humans with DS. Individuals with DS and Ts65Dn mice have deficits in bone mineral density (BMD), architecture, and bone strength. Over-expression of DYRK1A, a serine-threonine kinase encoded on Hsa21, has been linked to deficiencies in DS bone homeostasis. Epigallocatechin-3- gallate (EGCG), an aromatic polyphenol found in high concentrations in green tea, is a known inhibitor of Dyrk1a activity. Normalization of Dyrk1a activity by EGCG may have the potential to regulate bone homeostasis and increase BMD and bone strength in individuals with DS. In this study, we hypothesized that EGCG obtained from different sources would have differential effects in correcting bone deficits associated with DS. To test our hypothesis, we performed Liquid chromatography–mass spectrometry (LC-MS) on EGCG and related compounds from different sources. The LC-MS analysis determined the amount of EGCG and the degradation in our stock solution. Next, we treated three-weekold Ts65Dn and control male mice with EGCG for three weeks. At six weeks of age, mice were sacrificed. DXA and micro CT analysis were performed on the femurs and skulls of the mice to assess trabecular and cortical bone structure and BMD. Our results indicate the ability of EGCG to ameliorate skeletal deficiencies and compared pure EGCG with EGCG purchased from commercial vendors in correcting skeletal deficits associated with DS.